Antibodies for HIV prevention in young women

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 183-189

  Abdool Karim, Salim S ^a,b   Abdool Karim, Quarraisha ^a,b   Baxter, Cheryl ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Keywords HIV prevention; mAb; passive immunization; young women

Indexed keywords

ANTIRETROVIRUS AGENT; MONOCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AFRICA SOUTH OF THE SAHARA; CHIMERA; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; ADOLESCENT; ADULT; AFRICA; ANIMAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VULNERABLE POPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICA; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VULNERABLE POPULATIONS; YOUNG ADULT;

EID: 84928580450     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000147     Document Type: Review

References (52)

1. UNAIDS. The gap report. http://www.unaids.org/en/media/unaids/conten tassets/documents/unaidspublication/2014/UNAIDS-Gap-report-en.pdf [Accessed 16 October 2014]. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.
2. UNAIDS. UNAIDS report on the global AIDS Epidemic 2010. http://www. unaids.org/globalreport/[Accessed 11 February 2014]. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2010.
3. Abdool Karim Q, Abdool Karim SS, Singh B, et al. Seroprevalence of HIV infection in rural South Africa. AIDS 1992; 6:1535-1539.
4. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A turning tide among teenagers?. Cape Town: HSRC Press; 2009.
5. Abdool Karim S, Abdool Karim Q. The evolving HIV epidemic in South Africa. Int J Epidemiol 2002; 31:37-40.
6. Shisana O, Rehle T, Simbayi LC, et al. South African National HIV Prevalence, Incidence, and Behaviour Survey 2012. Cape Town: HSRC Press; 2014.
7. Department of Health. The 2012 National Antenatal Sentinel HIV & Herpes Simplex Type-2 Prevalence Survey in South Africa. Pretoria: Department of Health; 2014.
8. Ramjee G, Kapiga S, Weiss S, et al. The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr 2008; 47:93-100.
9. Nel A, Louw C, Hellstrom E, et al. HIV prevalence and incidence among sexually active females in two districts of South Africa to determine microbicide trial feasibility. PLoS One 2011; 6:e21528.
10. Nel A, Mabude Z, Smit J, et al. HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One 2012; 7:e35278.
11. Feldblum PJ, Latka MH, Lombaard J, et al. HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg, South Africa: A prospective study. BMJ open 2012; 2:e000626.
12. Ramjee G, Wand H, Whitaker C, et al. HIV incidence among nonpregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa. AIDS Behav 2012; 16:2062-2071.
13. Abdool Karim Q, Kharsany AB, Frohlich JA, et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 2011; 40:922-930.
14. Abdool Karim Q, Kharsany AB, Frohlich JA, et al. HIV incidence in young girls in KwaZulu-Natal, South Africa-public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav 2012; 16:1870-1876.
15. Abdool Karim SS, Richardson B, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2010; 25:957-966.
16. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
17. Centers for Diseases Control and Prevention. HIV transmission risk. 2013 [cited 9 February 2015]. http://www.cdc.gov/hiv/policies/law/risk.html
18. Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: A cohort study. Lancet 2010; 376:41-48.
19. Pettifor A, O'Brien K, Macphail C, et al. Early coital debut and associated HIV risk factors among young women and men in South Africa. Int Perspect Sex Reprod Health 2009; 35:82-90.
20. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: A meta-analysis. J Infect Dis 2002; 185:45-52.
21. Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490-497.
22. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: A key role in HIV incidence. AIDS 2009; 23:1595-1598.
23. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20:73-83.
24. Hallfors D, Cho H, Rusakaniko S, et al. Supporting adolescent orphan girls to stay in school as HIV risk prevention: evidence from a randomized controlled trial in Zimbabwe. Am J Public health 2011; 101:1082-1088.
25. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1transmission: A prospective cohort study. Lancet Infect Dis 2012;12:19-26.
26. Gregson S, Nyamukapa CA, Garnett GP, et al. Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet 2002; 359:1896-1903.
27. Kelly RJ, Gray RH, Sewankambo NK, et al. Age differences in sexual partners and risk of HIV-1 infection in rural Uganda. JAIDS 2003; 32:446-451.
28. MacPhail C, Williams BG, Campbell C. Relative risk of HIV infection among young men and women in a South African township. Int J STD AIDS 2002; 13:331-342.
29. Pettifor AE, Rees HV, Kleinschmidt I, et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 2005; 19:1525-1534.
30. Houlihan CF, Larke NL, Watson-Jones D, et al. HPV infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 2012; 26:2211-2222.
31. Abdool Karim Q. Barriers to preventing human immunodeficiency virus in women: experiences from KwaZulu-Natal, South Africa. J Am Med Womens Assoc 2001; 56:193-196.
32. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev 2009; CD003362.
33. Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: A systematic review and meta-analysis. Lancet Infect Dis 2009; 9:669-677.
34. Abdool Karim SS, Kashuba A, Werner L, Abdool Karim Q. Drug concentrations following topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
35. CONRAD. FACTS 001: safety and effectiveness of tenofovir gel in the prevention of human immunodeficiency virus (HIV-1) infection in young women and the effects of tenofovir gel on the incidence of herpes simplex virus (HSV-2) infection. http://clinicaltrials.gov/ct2/show/NCT01386294 [Accessed 20 September 2013].
36. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
37. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
38. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
39. Abdool Karim SS. HIV preexposure prophylaxis in injecting drug users. Lancet 2013; 381:2060-2062.
40. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083-2090.
41. U.S. Food andDrugAdministration.FDAapproves first drug for reducing the risk of sexually acquired HIV infection. 2012 [cited 9 February 2015]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.ht
42. Van Damme L, Corneli A, Ahmed K, et al. The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women [Abstract 32LB]. Conference of Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, WA.
43. Marrazzo JM, Ramjee G, Richardson BA, et al., for the VOICE Study Team. Tenofovir-based preexposure prophylaxis for HIV infection among African women. New Engl J Med 2015; 372:509-518.
44. Anderson PL, Lama JR, Buchbinder S, et al. Expanded case-control analysis of drug detection in the global iPrEx trial [abstractMOLBPE034]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy.
45. Garrett NJ, Werner L, Naicker N, et al. HIV disease progression in seroconvertors from the CAPRISA 004 Tenofovir Gel Preexposure Prophylaxis Trial. J AIDS 2015; 68:55-61.
46. Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341:1199-1204.
47. Falkowska E, Le KM, Ramos A, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014; 40:657-668.
48. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018.
49. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginalchallengewith a pathogenicR5simian/humanimmunodeficiency virus at serumlevelsgivingcompleteneutralizationin vitro. J Virol2001;75:8340-8347.
50. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012; 109:18921-18925.
51. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
52. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.